Literature DB >> 32152233

PIK3CA and p53 Mutations Promote 4NQO-Initated Head and Neck Tumor Progression and Metastasis in Mice.

Darío García-Carracedo1,2, Yi Cai2, Wanglong Qiu1,3, Kiyoshi Saeki1,3, Richard A Friedman1,4, Andrew Lee2, Yinglu Li5, Elizabeth M Goldberg5, Elias E Stratikopoulos6, Ramon Parsons6, Chao Lu5, Argiris Efstratiadis7, Elizabeth M Philipone8, Angela J Yoon8, Gloria H Su9,2,3.   

Abstract

The PI3K signaling pathway is frequently mutated in head and neck squamous cell carcinoma (HNSCC), often via gain-of-function (GOF) mutations in the PIK3CA gene. Here, we present novel genetically engineered mouse models (GEMM) carrying a GOF allele Loxp-STOP-Loxp(LSL)-PIK3CAH1047R (E20) alone or in combination with heterozygous LSL-p53+/R172H (p53) mutation with tissue-specific expression to interrogate the role of oncogenic PIK3CA in transformation of upper aerodigestive track epithelium. We demonstrated that the GOF PIK3CA mutation promoted progression of 4-nitroquinoline 1-oxide-induced oral squamous cell carcinoma (OSCC) in both E20 single mutant and E20/p53 double mutant mice, with frequent distal metastasis detected only in E20/p53 GEMM. Similar to in human OSCC, loss of p16 was associated with progression of OSCC in these mice. RNA-seq analyses revealed that among the common genes differentially expressed in primary OSCC cell lines derived from E20, p53, and E20/p53 GEMMs compared with those from the wild-type mice, genes associated with proliferation and cell cycle were predominantly represented, which is consistent with the progressive loss of p16 detected in these GEMMs. Importantly, all of these OSCC primary cell lines exhibited enhanced sensitivity to BYL719 and cisplatin combination treatment in comparison with cisplatin alone in vitro and in vivo, regardless of p53 and/or p16 status. Given the prevalence of mutations in p53 and the PI3K pathways in HNSCC in conjunction with loss of p16 genetically or epigenetically, this universal increased sensitivity to cisplatin and BYL719 combination therapy in cancer cells with PIK3CA mutation represents an opportunity to a subset of patients with HNSCC. IMPLICATIONS: Our results suggest that combination therapy of cisplatin and PI3K inhibitor may be worthy of consideration in patients with HNSCC with PIK3CA mutation. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32152233      PMCID: PMC7272268          DOI: 10.1158/1541-7786.MCR-19-0549

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  63 in total

1.  Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.

Authors:  Luc G T Morris; Barry S Taylor; Trever G Bivona; Yongxing Gong; Stephanie Eng; Cameron W Brennan; Andrew Kaufman; Edward R Kastenhuber; Victoria E Banuchi; Bhuvanesh Singh; Adriana Heguy; Agnes Viale; Ingo K Mellinghoff; Jason Huse; Ian Ganly; Timothy A Chan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 2.  Class I PI3K in oncogenic cellular transformation.

Authors:  L Zhao; P K Vogt
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

Review 3.  TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.

Authors:  Ge Zhou; Zhiyi Liu; Jeffrey N Myers
Journal:  J Cell Biochem       Date:  2016-06-03       Impact factor: 4.429

4.  A high prevalence of p53 mutations in pre-malignant oral erythroplakia.

Authors:  G Z Qin; J Y Park; S Y Chen; P Lazarus
Journal:  Int J Cancer       Date:  1999-01-29       Impact factor: 7.396

5.  A region within murine chromosome 7F4, syntenic to the human 11q13 amplicon, is frequently amplified in 4NQO-induced oral cavity tumors.

Authors:  B Yuan; M N Oechsli; F J Hendler
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

6.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

7.  Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.

Authors:  Elias E Stratikopoulos; Meaghan Dendy; Matthias Szabolcs; Alan J Khaykin; Celine Lefebvre; Ming-Ming Zhou; Ramon Parsons
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

Review 8.  Cisplatin: mode of cytotoxic action and molecular basis of resistance.

Authors:  Zahid H Siddik
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

9.  Overexpression of PIK3CA in murine head and neck epithelium drives tumor invasion and metastasis through PDK1 and enhanced TGFβ signaling.

Authors:  L Du; X Chen; Y Cao; L Lu; F Zhang; S Bornstein; Y Li; P Owens; S Malkoski; S Said; F Jin; M Kulesz-Martin; N Gross; X-J Wang; S-L Lu
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

10.  Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Authors:  Jeffrey A Engelman; Liang Chen; Xiaohong Tan; Katherine Crosby; Alexander R Guimaraes; Rabi Upadhyay; Michel Maira; Kate McNamara; Samanthi A Perera; Youngchul Song; Lucian R Chirieac; Ramneet Kaur; Angela Lightbown; Jessica Simendinger; Timothy Li; Robert F Padera; Carlos García-Echeverría; Ralph Weissleder; Umar Mahmood; Lewis C Cantley; Kwok-Kin Wong
Journal:  Nat Med       Date:  2008-11-30       Impact factor: 53.440

View more
  5 in total

1.  Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers.

Authors:  Samantha M Y Chen; Vince Popolizio; Rachel A Woolaver; Huaibin Ge; Alexandra L Krinsky; Jessy John; Etienne Danis; Yao Ke; Yonatan Kramer; Li Bian; Andrew G Nicklawsky; Dexiang Gao; Silvia Liu; Zhangguo Chen; Xiao-Jing Wang; Jing H Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-04-02

2.  Physapruin A Enhances DNA Damage and Inhibits DNA Repair to Suppress Oral Cancer Cell Proliferation.

Authors:  Tzu-Jung Yu; Ching-Yu Yen; Yuan-Bin Cheng; Chia-Hung Yen; Jiiang-Huei Jeng; Jen-Yang Tang; Hsueh-Wei Chang
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

3.  The regulation of long non-coding RNA 00958 (LINC00958) for oral squamous cell carcinoma (OSCC) cells death through absent in melanoma 2 (AIM2) depending on microRNA-4306 and Sirtuin1 (SIRT1) in vitro.

Authors:  Lei Jiang; Wenyu Ge; Yifei Cui; Xiaofeng Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Stromal cells in the tumor microenvironment promote the progression of oral squamous cell carcinoma.

Authors:  Qiusheng Shan; Kiyofumi Takabatake; Haruka Omori; Hotaka Kawai; May Wathone Oo; Keisuke Nakano; Soichiro Ibaragi; Akira Sasaki; Hitoshi Nagatsuka
Journal:  Int J Oncol       Date:  2021-08-09       Impact factor: 5.650

5.  Dendrobine suppresses endoplasmic reticulum stress-induced apoptosis through upregulating microRNA miR-381-3p to decrease caspase-4.

Authors:  Jing Meng; Xiaoying Song; Guoliang Yan; Haihui Wang; Haitao Li; Danfei Lou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.